Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks ninlaro safety in chinese myeloma patients

NCT ID NCT04328662

Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the safety of the drug Ninlaro (ixazomib) when used to treat multiple myeloma in everyday medical practice in China. About 482 patients were observed, and researchers recorded any side effects or dose changes. The goal was to gather real-world safety information, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

482 people

The number who actually took part.

Started

May 2020

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Chinese participants with RRMM who have received at least one dose of IRd or non-IRd ixazomib based regimen treatment, and NDMM and non-myeloma who have received at least one dose of ixazomib-based regimen treatment will be observed prospectively.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Undergoing treatment with Ninlaro (of less than 3 months from initial treatment with Ninlaro) or to be prescribed with Ninlaro capsule. 2. Participants will be able to sign Informed Consent Form to participate. Exclusion Criteria: 1. Currently participates or plans to participate in any interventional clinical trial. 2. Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma Neoplasms, plasma cell

Contacts and locations

Locations

  • Affiliated Hospital of Jining Medical College

    Jining, Shandong, 272007, China

  • Anhui Cancer Hospital

    Hefei, Anhui, 230031, China

  • Beijing Chao-yang Hospital,Capital Medical University

    Beijing, Beijing Municipality, 100020, China

  • Beijing Chao-yang Hospital,Capital Medical University(Shijingshan)

    Beijing, Beijing Municipality, 100043, China

  • Beijing Jishuitan Hospital

    Beijing, Beijing Municipality, 100035, China

  • Datong Third People's Hospital

    Datong, Shanxi, 037046, China

  • Hainan General Hospital

    Haikou, Hainan, 570311, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, 150081, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450003, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

  • Shanxi Provincial People's Hospital

    Taiyuan, Shanxi, 030012, China

  • Shaoxing People's Hospital

    Shaoxing, Zhejiang, 312099, China

  • Soochow Hongci Blood Disease Hospital

    Suzhou, Jiangsu, 215100, China

  • Sun Yat-Sen Memorial Hospital

    Guangzhou, Guangdong, 510120, China

  • Tai'an Central Hospital

    Tai’an, Shandong, 271099, China

  • Taizhou First People's Hospital

    Taizhou, Zhejiang, 318020, China

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, 116011, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215006, China

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, 110001, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510630, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

  • Wuxi People's Hospital

    Wuxi, Jiangsu, 214023, China

  • Zhabei Central Hospital, Jing'an District, Shanghai

    Shanghai, Shanghai Municipality, 200070, China

  • Zhujiang Hospital, Southern Medical University

    Guangzhou, Guangdong, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.